Search
Population Heath Partners Managing Partner and former Metsera CEO Whit Bernard shares his take on the state of the obesity market and more
He shares his thoughts on recent data we have seen from mechanisms such as INHBE and amylin, why he's a big believer in oral therapies, and what other ares of biotech excite him today.
13 hours ago
Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA
He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the...
Jul 22, 2025
Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides
He describes how Metsera, which had its IPO two months ago, is aiming to develop a differentiated GLP-1 vs currently marketed products by...
Apr 23, 2025
.png){kind=logo}
